Kailo Pharma
About Kailo Pharma
Kailo Pharma is a Healthtech startup based in Nazareth, Israel that has raised $2.1M in venture capital across 1 funding round. The company reached Pre-Seed stage in March 2026 with a $2.1M round led by NGT HealthCare. Kailo Pharma's investor base includes 1 institutional fund, with NGT HealthCare leading the most recent equity round.
Kailo Pharma is an Israeli biopharmaceutical startup developing the first drug specifically designed to treat post-traumatic stress disorder (PTSD) by targeting its root cause. The company is advancing a peptide-based nasal spray discovered at the University of Haifa that blocks the brain mechanism responsible for pathological amplification of traumatic memories. Kailo Pharma is jointly owned by the University of Haifa's technology transfer company (Carmel) and NGT Healthcare II.
Kailo Pharma Funding Rounds Timeline
1 rounds · $2.1M raised
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Pre-Seed | March 2026 | $2.1M | — | NGT HealthCare | — |
Investors in Kailo Pharma
1 institutional investors across 1 rounds
Lead investors
Recent news about Kailo Pharma
- FundingKailo Pharma Raises Approx. $2.1M in Pre-Seed FundingMarch 2026
Questions about Kailo Pharma
How much has Kailo Pharma raised?
Kailo Pharma has raised $2.1M across 1 funding round since null.
Who are the investors of Kailo Pharma?
Kailo Pharma's investors include NGT HealthCare.
When was Kailo Pharma's last funding round?
Kailo Pharma's most recent round was a $2.1M Pre-Seed in March 2026, led by NGT HealthCare.